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1. Introduction 
There is consensus that endovascular aneurysm repair (EVAR) offers several benefits when 
compared to open repair of abdominal aortic aneurysm (AAA). Although originally 
introduced for patients considered unfit for major surgery. (Parodi, 1991) EVAR has been 
used increasingly in patients judged fit for open repair (OR). Results of randomized trials 
demonstrated that the 30-day mortality in such patients is 2%. (EVAR trial 1 participants, 
2005; Prinssen 2004) 
The results of the EVAR-2 trial stunned the vascular community. The high mortality rates 
(9% at 30 days and 64% at 4 years) in the EVAR arm elicited trepidation that the minimally 
invasive approach may afford no benefit compared with the natural history of untreated 
AAAs in high-risk patients. (EVAR trial 2 participants, 2005) However, subsequent data 
from the Society for Vascular Surgery (SVS) Lifeline Registry (Sicard, 2006) and the Veterans 
Affairs National Surgical Quality Improvement Program (Bush, 2007) have shown that 
EVAR benefits many patients who fulfilled the EVAR-2 high-risk criteria by curtailing 
perioperative sequelae. 
All of these published studies used objective endpoints of morbidity and mortality. 
However, in a high-risk cohort, the issue of quality of life in terms of years gained needs to 
be addressed, as well as the broader issue of the cost to society. There are also questions as 
to which patients are going to die from something else before they benefit from the 
aneurysm repair, which patients should not be treated, and what happens to patients who 
choose non-interventional management. These are complex issues, so it is necessary to 
approach optimizing AAA treatment of high-risk patients from a number of perspectives. 
Clinically, we need to verify the efficacy and safety of each treatment option and identify if a 
subgroup exists in which repair poses more of a risk than a benefit. Secondly, from the 
patient’s viewpoint, what price is he/she willing to pay for quality of life? Finally, how 
much is the healthcare system keen to invest for optimal AAA treatment? 
The aim of our study was to scrutinize EVAR as a feasible treatment option for high risk 
patients and elucidate whether it can enhance survival and quality of life in a cost-effective 
manner. 
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2. Methods 
2.1 Study design 
In 2002, a prospective study was designed to compare EVAR to open repair or best medical 
therapy (BMT) in high-risk AAA patients with aneurysms deemed suitable for EVAR. 
Patients with AAAs >4.5 cm on the initial duplex ultrasound had computed tomographic 
angiograms (CTA), which were scored for anatomical severity and EVAR suitability using 
guidelines from the Society for Vascular Surgery/American Association for Vascular 
Surgery (SVS/ AAVS). (Chaikof, 2002) Based on these recommendations, patients were 
assigned co-morbidity scores and classified as high risk if they were >60 years old and had 
at least one of the following co-morbidities: 
 symptomatic congestive heart failure,  
 valvular heart disease,  
 cardiac arrhythmia,  
 chronic obstructive pulmonary disease, or  
 chronic kidney disease (kidney damage, a glomerular filtration rate,60 mL/min/1.73 
m2 for 3 or more months regardless of the underlying etiology, or serum creatinine .200 
mmol/L).  
The decision on the management modality took into consideration life expectancy, operative 
risk, and risk of rupture, (Dorros, 1997; Sultan , 2001) but the ultimate decision was made by 
the patient after an adequate understanding of each procedure’s risks and benefits had been 
discussed with the patient, the family, and the primary care physician.  
Eligible patients electing BMT received a statin, a cardioselective beta-blocker, aspirin (300 
mg/d), and clopidogrel (75 mg/d). Patients opting for intervention were also prescribed this 
pharmacological combination; however, clopidogrel was introduced only postoperatively. 
(Oaikhinan, 2004).  
It is our policy that once a patient is deemed very high risk for elective AAA repair, the risk 
of survival following emergent repair does not warrant an attempt at surgery. Therefore, 
once a decision not to operate was taken, a red label was placed on the patient’s hospital 
chart indicating that a decision not to operate had been made should the patient present to 
our Accident and Emergency Department with rupture. (Hynes, 2005) 
2.2 Patient enrollment 
Between January 2002 and January 2007, 1083 patients were referred to our tertiary care 
university center for evaluation of their aortic disease. Of these, 162 patients (119 men; mean 
age 76 years) were classified as high risk and had aneurysms anatomically suitable for 
EVAR. Fifty-two patients (36 men; mean age 74.6+/-7.3 years) had open repair, 66 (52 men; 
mean age 72.6+/-6.3 years) underwent EVAR, and 44 (31 men; mean age 80.9+/-6.7 years) 
were managed medically. All patients had the treatment that was originally decided upon.  
All patients were classified as ASA (American Society of Anesthesiologists) III or IV; more 
than half (54%) of the OR group were ASA IV compared to 62% of the EVAR group and 80% 
of the non-operative group. 
2.3 Follow-up protocols 
EVAR patients had a plain abdominal radiograph (anteroposterior and lateral views) and 
color duplex ultrasound prior to discharge. They had a repeat color duplex ultrasound and 
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radiograph at 6 weeks, 3 months, 6 months, and 6-month intervals thereafter. CT scans were 
performed at 6 months and then yearly, unless there was evidence of sac expansion or 
substantial endoleak on duplex ultrasound or migration was noted on the radiograph. 
Following open repair, patients were seen at 6 weeks, at 6-month intervals for 18 months, 
and yearly thereafter. OR patients had clinical examination and ankle-brachial index 
measurements at 6 weeks and clinical examination at subsequent visits. Duplex ultrasound 
or CT examination was performed if clinically indicated or the patient became symptomatic.  
BMT patients were followed at 6-month intervals with color duplex ultrasound at each visit. 
2.4 Endpoints 
The primary clinical endpoint was survival without aneurysm-related death. Cause of death 
was obtained from primary healthcare physicians if the death occurred outside our hospital 
or from medical records if the death occurred in hospital. All ruptures were confirmed by 
CT and/or autopsy. Secondary endpoints were freedom from all-cause mortality, secondary 
intervention, and major adverse clinical events (death, myocardial infarction, major 
amputation, cerebrovascular accident, respiratory morbidity requiring reintubation 
with/without tracheostomy, or renal failure requiring dialysis). 
The two quality-of-life endpoints were cost per QALY (quality-adjusted life years) and 
TWIST (time spent without symptoms of disease and toxicity of treatment), a special 
QALY endpoint incorporating both length and quality of life. (Gelber, 1989) TWIST was 
useful for treatment comparison by compensating for situations when differences in 
aneurysm-related mortality were statistically significant but overall survival differences 
were not, since it acknowledges that extensions to disease-free time may be at the expense 
of treatment toxicity. To integrate quality and quantity of life, the quality-adjusted time 
with and without symptoms or toxicity (Q-TWIST) was used as a natural extension of the 
quality-of-life– oriented TWIST endpoint. QTWIST was an adaptation of the concept of 
QALYs; the methodology was extended so that periods spent with toxicity or relapses 
were included in the analysis but weighted to represent their quality value relative to 
TWIST. This allowed us to look at the intervention and the health effects persisting 
beyond the perioperative period. 
In this study, the Q-TWIST was the sum of the quality-adjusted time (u) spent undergoing 
treatment and experiencing toxicity (TOX, i.e., hospital stay associated with the primary 
intervention including perioperative morbidity and mortality) plus the time spent free of 
disease in perfect health (TWIST), plus the time spent experiencing symptoms of disease 
relapse (REL, i.e., hospital stay associated with any secondary intervention including 
perioperative morbidity and mortality). In the formula for Q-TWIST (utTOX + TWIST + 
urREL), the utility values ut and ur associated with the periods of survival for both EVAR 
(ut50.7, ur50.7) and open repair (ut50.56, ur50.7) were based on sensitivity values from the 
Interim Report on the Cost-Effectiveness of Elective Endovascular Repair Compared to 
Open Surgical Repair of Abdominal Aortic Aneurysms prepared for the Ontario Ministry of 
Health and Long-term Care. (Bowen, 2005) The quality adjusted time utility for the BMT 
group in this study was u50.56. 
2.5 Statistical analysis 
The anatomical severity scores were correlated with technical success, endoleak rate, 
migration, conversion rate, and the need for secondary intervention. Prediction of 
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perioperative outcome was assessed using the Kertai customized probability model based 
on a combination of clinical predictors, type of vascular surgery, and concomitant 
medication use. (Kertai, 2005) 
Cumulative rates for survival without aneurysm-related or all-cause death were estimated 
using Kaplan-Meier analysis; curves were compared using the log-rank test. Due to the 
risks of informative censoring and biased Kaplan-Meier estimates of the survival function, 
a partitioned survival analysis was performed.(Glasziou, 1998) Overall survival was 
partitioned into the time spent in each health state, i.e., time spent without symptoms or 
toxicity from treatment was separated from time spent with toxicity of treatment and with 
secondary intervention. The mean duration in each state for each group was combined as 
a weighted sum according to the Q-TWIST model. Weighting the time spent in each 
health state at the group level, rather that at the individual level, avoided the need to 
weigh censored survival times and thus overcame the problem of informative censoring. 
Kaplan-Meier survival curves corresponding to each transition time were overlaid on one 
graph to show the partitioning of overall survival. The upper time limit for the analysis, 
48 months, was based on the follow-up time of the study cohort and was chosen to reduce 
censoring. 
The influence of co-morbid factors on outcome was determined using Cox proportional 
hazards models. The risk of a complication after open repair was compared with that after 
EVAR; the results are presented as risk ratios (RR) with 95% confidence intervals (CI). 
Differences among treatment groups were evaluated with ANOVA and the Mann-Whitney 
U test for continuous variables or Fisher exact test for proportions. Differences among 
groups were taken as significant if p<0.05. 
2.6 Cost analysis 
The total costs per procedure, inclusive of follow-up, were calculated to estimate the cost per 
QALY and the incremental cost-effectiveness ratio of an EVAR program relative to the 
standard open repair program. The incremental cost effectiveness ratio was determined by 
measuring the incremental benefits (in life years) for the new intervention (EVAR) and 
dividing it by the incremental cost relative to current practice (cost of open repair). 
A relative value unit (RVU) cost accounting system, which included both direct and 
indirect expenses, was used at our hospital. (Finkler, 1999; West, 1996)  Individual charge 
items were assigned a weight or RVU. Expenses from revenue generating centers were 
allocated to each of the charge items within a department according to category, such as 
labor, supplies, equipment depreciation, and overhead. The cost per category was derived 
from each charge item on the basis of its RVU. Mean hospital costs and mean diagnostic-
related group (DRG)–weighted payments were analyzed to determine net profit or loss 
for the hospital. The DRG codes for AAA repair were F08A (major reconstruct vascular 
procedures without cardiopulmonary bypass pump with catastrophic CC) and F08B 
(major reconstruct vascular procedures without cardiopulmonary bypass pump without 
catastrophic CC). 
Data from our cost analysis were correlated with allocations to our hospital by the 
National Health Service Executive for the relevant DRG codes. The RVU used for a DRG 
was based on amalgamated data from the 9 main Irish National University Teaching 
Hospitals. 
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3. Results 
Although patients in the BMT group were on average older (p<0.0001), there was no 
significant difference in the proportion of patients with major cardiac (p=0.104), pulmonary 
(p=0.170), or renal (p=0.108) diseases among the 3 groups (Table 1).  
 
 OR EVAR BMT p 
Number 52 66 44  
Aneurysm Diameter, cm 6.2+/-1.6 5.4+/-1.1 6.2+/-1.7 0.005* 
Age, y 74.6+/-7.3 72.6+/-6.3 80.9+/-6.7 <0.0001* 
Cardiac 
Ischaemic Heart Disease 
Congestive Cardiac Failure 
27 (51.9%) 
25 (48.1%) 
19 (36.5%) 
38 (57.6%) 
39 (59.1%) 
34 (51.5%) 
32 (72.3%) 
36 (68.2%) 
27 (61.4%) 
0.104 
0.137 
0.047* 
Respiratory Disease 23 (44.3%) 40 (60.6%) 26 (59.1%) 0.170 
Renal Impairment 18 (34.6%) 25 (37.9%) 24 (54.6%) 0.108 
Hypertension 34 (65.4%) 45 (68.2%) 28 (63.6%) 0.881 
Cerebrovascular Disease 12 (23.1%) 17 (25.8%) 8 (18.2%) 0.654 
Mean SVS combined Co-morbidity 
Severity Score 
7.75 9.89 11.1 0.057 
Mean Kertai Customised Probability 
Index 
28.0 34.4 35.6 0.070 
Continuous data are presented as means ± standard deviation; categorical data are given as counts 
(percentages). 
BMT: best medical treatment; EVAR: endovascular aneurysm repair; OR: open repair  
Table 1. Demographics and Risk Factors for the 3 Treatment Groups 
The mean aneurysm size was smaller in the EVAR group (mean 5.4±1.1cm; p=0.005) versus 
OR (mean 6.2±1.6cm) or BMT (mean 6.2±1.7cm). There were also no significant differences 
in the proportions of hypertensive patients (p=0.881). 
All patients were anatomically suitable for EVAR, and the proportion of patients at 
moderate to severe risk of access failure, endograft limb obstruction, or embolisation was 
not statistically different among the groups (Table 2). However, using the strict SVS/AAVS 
scoring system, the proportion of patients at moderate to severe risk of endoleak was zero in 
the EVAR group (p=0.008), while the proportion of patients at moderate to severe risk of 
failed deployment was highest in the BMT group (p=0.015). 
 
 OR EVAR BMT  
Global score for risk of major morbidity and 
mortality after endograft repair ≥2 39% 57% 65% P=0.079 
Anatomic score of risk of access failure or 
endograft limb obstruction ≥2 76% 57% 86% P=0.008* 
Anatomic score of risk of embolization ≥2 85% 77% 95% P=0.053 
Anatomic score of risk of endoleak ≥2 30% 0% 56% P<0.0001* 
Anatomic score of risk of failed deployed ≥2 39% 43% 79% P=0.0003* 
BMT: best medical treatment; EVAR: endovascular aneurysm repair; OR: open repair  
Table 2. Anatomical Severity Scores 
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3.1 Initial outcomes 
In the EVAR group, all but 2 procedures were completed satisfactorily. An 82-year-old man 
with severely calcified iliac arteries was converted to open repair following right common 
iliac artery perforation and a 79 year-old woman implanted with a Quantum device that 
failed to deploy properly was treated with a silver-impregnated Dacron graft. 
Insofar as operative details are concerned, the mean length of the operation was 
considerably reduced in the EVAR group (169 minutes) compared to the open repair group 
(193 minutes; p=0.04). The need for blood transfusions was also significantly lower in the 
EVAR group (mean 0.6 units) versus the open group (mean 1.8 units; p=0.015). 
There was no significant difference in the mean rise in postoperative creatinine between the 
groups (p=0.845). 
Mean lengths of hospital and intensive care unit (ICU) stay were reduced with EVAR (10.2 
and 0.5 days, respectively) compared with OR (20.4 and 6.8 days, respectively; p<0.0001 for 
both). In the EVAR group, 11 type II endoleaks were noted on postoperative duplex and/or 
CT scans; all resolved spontaneously. 
3.2 Clinical endpoints 
Compared to open repair, the 30-day morbidity was significantly improved for EVAR 
patients (6% versus 23%; p=0.007), but 30-day mortality was not different between EVAR 
(3.0%) and OR (5.8%; p=0.653).  
At 30 days, freedom from MACE was similar for EVAR (95.5%) and OR (88.5%; p=0.173, 
RR=0.39, 95% CI 0.10 to 1.46). At 4 years, freedom from MACE was significantly improved 
with EVAR (77.5%) compared with BMT (27.9%; p=0.001, RR=0.32, 95% CI 0.17 to 0.61) and 
similar to OR (75.4%; p=0.519, RR=0.76, 95% CI 0.33 to 1.73).  
Mean follow-up was 22.7+/-16.1 months; no patient was lost to follow-up. There were 2 
(3.0%) aneurysm-related deaths in the EVAR group, while in the BMT group, 11 (25%) 
ruptures occurred over the study period, 5 within 6 months of diagnosis. Nine of these BMT 
rupture patients presented to the hospital, and each had a CT scan that confirmed rupture; 
none of these patients was operated upon. The 2 remaining patients died in the community, 
and autopsy reports cited AAA rupture as the cause of death. 
At 1 year, the chance of survival without aneurysm-related death was 12.2% higher in the 
EVAR group compared to the BMT group (p=0.049, RR=0.23, 95% CI 0.06 to 0.94). This 
survival benefit increased with time, and at 4 years, the survival without aneurysm-related 
death (Figure 1) was significantly greater in the EVAR group (96.7%) compared to BMT 
(66.8%; p=0.002, RR=0.08, 95% CI 0.02 to 0.26), but it was not statistically different from OR 
(93.9%; p=0.483, RR 0.53, 95% CI 0.09 to 3.09). 
Only 2 factors were found to adversely influence survival without aneurysm-related death 
(Table 3): age (p=0.034, RR=1.09, 95% CI 1.01 to 1.18) and aneurysm size (p=0.004, RR=1.51, 
95% CI 1.14 to 2.00). 
Four-year cumulative survival without death from any cause (Figure. 2) following EVAR 
(78.8%) was not statistically different from OR (84.9%; p=0.590, RR=1.30, 95% CI 0.50 to 
3.36), but was significantly improved compared to BMT (27.9%; p<0.001, RR=0.30, 95% CI 
0.16 to 0.57). As with aneurysm-related mortality, only age (p=0.014, RR=1.06, 95% CI 1.01 to 
1.10) and aneurysm size (p=0.001, RR=1.35, 95% CI 1.13 to 1.62) were found to influence 
freedom from all-cause mortality (Table 4). 
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Risk Factor Risk Ratio 95% CI p 
Age 1.0889 1.0066 to 1.1780 0.0337* 
Male 1.8064 0.5052 to 6.4596 0.3630 
Cardiac 1.9562 0.4893 to 7.8202 0.3426 
Respiratory 2.0177 0.5885 to 6.9174 0.2641 
Renal 1.9054 0.6416 to 5.6588 0.2457 
Hypertension 1.1772 0.3613 to 3.8357 0.7866 
Diabetes 1.2693 0.4514 to 3.5691 0.6512 
Smoking 0.6712 0.2459 to 1.8323 0.4365 
Aneurysm Diameter 1.5098 1.1410 to 1.9977 0.0039* 
 
 
CI: confidence interval. 
Table 3. Results of the Cox Proportional Hazards Model for Aneurysm-Related Mortality 
 
 
 
 
 
At 4 years, EVAR (96.7%) vs. OR (93.9%; p50.483, RR50.53, 95% CI 0.09 to 3.09) or vs. BMT (66.8%; 
p50.0021, RR50.08, 95% CI 0.02 to 0.26). 
BMT: best medical treatment; EVAR: endovascular aneurysm repair; OR: open repair  
Fig. 1. Aneurysm-related Kaplan-Meier survival curves. 
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Fig. 2. All-cause Kaplan-Meier survival curves. At 4 years, EVAR (78.8%) vs. OR (84.9%; 
P=0.59, RR=1.3, 95% CI 0.50 to 3.36) or vs. BMT (27.9%; p=0.0005, RR=0.30, 95% CI 0.16 to 
0.57). 
 
Risk Factor Risk Ratio 95% CI p 
Age 1.0555 1.0109 to 1.1020 0.0141* 
Male 1.7141 0.8223 to 3.5731 0.1505 
Cardiac 1.3501 0.6614 to 2.7559 0.4097 
Respiratory 1.3264 0.6781 to 2.5942 0.4093 
Renal 1.3485 0.7273 to 2.5002 0.3426 
Hypertension 1.2164 0.6265 to 2.3616 0.6605 
Diabetes 1.3173 0.7217 to 2.4045 0.3693 
Smoking 1.2317 0.6749 to 2.2479 0.4972 
Aneurysm Diameter 1.3495 1.1276 to 1.6151 0.0011* 
CI: confidence interval. 
Table 4. Results of the Cox Proportional Hazards Model for All-Cause Mortality 
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3.3 Secondary interventions 
Over the observation period, there were 3 secondary interventions in the EVAR group 
versus 1 among the OR patients. Thus, at 4 years, the intervention-free survival rate for 
EVAR (94.5%) was similar to OR (98.1%, p=0.410, HR=2.51, 95% CI 0.35 to 18.0). In the OR 
group, an 80-year-old woman suffered distal embolization; femoral thromboembolectomy, 
endarterectomy, and femorofemoral bypass grafting were done 72 hours postoperatively. 
Two EVAR patients had limb sequelae: a 76-year-old man had a kink develop in the 
contralateral limb due to aneurysm tortuosity and an 83-year-old man had a thrombosed left 
graft limb 1 year post EVAR. Both were treated with endovascular techniques and 
recovered. The third secondary procedure was done in an 82-year-old woman with a type III 
endoleak diagnosed on the postoperative duplex scan. An aortic cuff and iliac extension 
were placed 3 days after her primary procedure. 
3.4 Quality of life assessment 
Over a 4-year follow-up period, the QTWIST was 3.64 years for EVAR and 3.60 years for 
OR. The 28% 4-year freedom from all-cause mortality in the BMT group resulted in only a 
2.22-year Q-TWIST for every 4 years of treatment. Sensitivity analysis showed that Q-TWIST 
was significantly improved with EVAR compared to OR over a full range of utility values 
between 0 and 1 (p<0.003; Table 5).  
 
EVAR vs. Open Repair 
Utility for TOX 
Utility for 
Relapse 
0 0.25 0.50 0.75 1.0 
0 0.0029 0.0028 0.0027 0.0026 0.0025 
0.25 0.0030 0.0028 0.0027 0.0027 0.0026 
0.50 0.0030 0.0029 0.0028 0.0027 0.0026 
0.75 0.0031 0.0029 0.0028 0.0027 0.0027 
1.0 0.0031 0.0030 0.0029 0.0027 0.0027 
EVAR vs. Best Medical Therapy 
Utility for TOX 
Utility for 
Relapse 
0 0.25 0.50 0.75 1.0 
0 0.039 0.044 0.05 0.057 0.064 
0.25 0.040 0.045 0.05 0.057 0.064 
0.50 0.040 0.045 0.05 0.059 0.066 
0.75 0.041 0.046 0.05 0.059 0.066 
1.0 0.041 0.046 0.05 0.060 0.067 
Table 5. Threshold Utility Analyses 
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3.5 Cost analysis 
In the analysis of costs (Table 6), 52 high-risk patients were treated with OR over a 5-year 
period (2002–2007) at a total inpatient cost of €1,257,457. The 66 patients treated with EVAR (14 
patients more than OR) incurred a lower cost of €1,129,138. If the cost of follow-up over 4 years 
was included, the mean costs per patient were €18,476 for EVAR and €24,252 for OR, a savings 
of €5,776 per patient treated with EVAR. The in-hospital costs were €17,108 for EVAR and 
€24,182 for OR. For the F08A code, our hospital was assigned a RVU of 5.44 and was allocated 
€23,453 in our budget. For the F08B code, our hospital was assigned a RVU 2.44, providing a 
budgetary allocation of €10,625. Thus, for AAA repair, EVAR generated a net profit of € 6345 
per case for the hospital, while OR was done at a net loss of €729 per case. 
 
Costs  EVAR (n=66) OR (n=52) BMT (n=44) 
Pre-op work-up     
CTAngiogram €600 €39,600 €31,200 €26,400 
Chest X-ray €88 €5,779 €4,553 €3,853 
Duplex Screening €185 €12,210 €9,620 €8,140 
Echocardiogram €145 €9,570 €7,540 €6,380 
Pulmonary function Tests €125 €8,250 €6,500 €5,500 
Pharmacy, transfusion and 
Laboratory costs 
€305-€415 €27,390 €21,580 €13,420 
Accomodation     
Hospital Bed per diem €540 €348,300 €382,860 €23,760 
ICU Bed per diem €1,646 €51,018 €582,592  
Theatre     
Per diem Theatre Overheads 
(inc. Staffing, Radiology etc) 
€6,402 €105,630 €166,447  
Equipment     
Graft (Intervascular) €915 €1,830 €47,580  
Graft (Dynaflo) €625 €11,250 €625  
Endograft €7,000 €462,000   
Catheters/Wires/Balloons 
etc 
€635 €41,941   
Embolisation     
Coils €554 €1,659   
Catheters/Wires/Balloons 
etc 
€359 €1,077   
Bed Stay €545 €1,635   
Total-In-Patient Cost  €1,129,138 €1,257,457 €87,453 
Follow-up     
Vascular Laboratory €150 €33,150 €3,640 €23,350 
PFA €88 €19,351   
CTA €300 €37,800   
Total Cost  €1,219,439 €1,261,097 €110,803 
Mean Cost per Patient  €18,476 €24,252 €2,518 
Q-TWiST  3.64years 3.60years 2.22years 
QALY  0.91 0.90 0.56 
Cost per QALY  €5,076 €6,737 €1,134 
Table 6. Cost Analysis 
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Treatment with EVAR cost €5076 per QALY, which was €1661 less than OR, giving a 
negative incremental cost-effectiveness ratio (ICER) for EVAR versus OR of €144,388 per 
QALY gained. EVAR was €3,942 more expensive per QALY than BMT alone; the ICER was 
€45,595 per QALY gained with EVAR versus BMT. 
4. Dicussion 
At present, considerable controversy exists in the vascular community regarding optimum 
management of high-risk patients with large AAAs. There has been a remarkable 
convergence of data from randomized trials giving level-1 evidence that EVAR reduces 
operative mortality by two thirds compared with open repair; the survival benefit is 
sustained over intermediate-term follow-up in low- to intermediate risk patients.(EVAR 
trial-1 participants, 2005; Prinssen, 2004) However, the results of these trials cannot be 
generalized to patients who are at high risk for open repair. The patients in EVAR 2 (EVAR 
trial-2 participants, 2005) were older and had more cardiovascular co-morbidities; this was 
reflected in the high 9% 30-day mortality rate and a 4-year survival of only 36%. Moreover, 
there was considerable crossover between the trial groups and after randomization to the 
non-intervention group, 20% of patients subsequently underwent elective repair of their 
aneurysm. Furthermore, the trial was not limited to an objective list of high-risk criteria, 
which led to a lack of objectivity and uniformity in what is truly a high-risk patient. This 
biased the study against EVAR and weakened the investigators conclusions that 
prophylactic operations designed to improve survival cannot be effective in patients with 
short life expectancy. They concluded that EVAR is much more costly than no intervention, 
without a survival benefit in high-risk patients. 
Our results show that EVAR can be safely performed in high-risk patients. Our 30-day 
perioperative mortality (3%) rate was considerably lower than the EVAR-2 trial. However, 
although we saw a clear advantage at 4 years with EVAR versus BMT, we did not see a clear 
benefit in terms of all-cause mortality for EVAR versus open repair. When interpreting these 
results, one has to question the merits of using all-cause mortality as a primary endpoint for 
a study on a specific treatment. All-cause mortality is an extremely important variable, but it 
is a metric of limited value when assessing a disease-specific treatment in a senior citizen 
population. This is best illustrated if you consider that 48 patients in EVAR 1 (EVAR trial-1 
participants, 2005) died from cancer, representing about one third of the overall mortality 
over the study period. These cancer deaths diluted the overall survival benefit conferred by 
EVAR over open repair. It appeared more logical to us to use survival without aneurysm-
related death as our primary endpoint, but here too, the difference between EVAR and OR 
was not significant, likely due to our high OR survival rate and low morbidity in the context 
of high-risk patients. This means that a large cohort is needed to show statistical significance 
without risk of a type II error. However, it confirms that high-risk patients can still 
experience low perioperative morbidity and high midterm survival if they are treated in 
centers with high-volume practice and appropriate preoperative patient assessment, optimal 
selection of operative strategy, careful intraoperative anesthetics management, meticulous 
attention to operative technical detail, and skilled postoperative management. 
At 6 months, a significant 9.3% survival benefit was seen with EVAR compared to BMT. Fully 
half of the deaths in the non-operative group were due to rupture, and 50% of the ruptures 
occurred within the first 9 months, which helped to increase the benefit with EVAR to 30% at 4 
years. The survival curves for EVAR and non-operative management continue to diverge after 4 
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years, which contrasts to the EVAR-2 trial, (EVAR trial-2 participants, 2005) in which a high 
operative mortality rate meant that no late difference in aneurysm related mortality and no 
difference in overall survival were seen despite more deaths occurring from aneurysm rupture 
in the non-intervention group. We are not alone in establishing that favorable outcomes are 
possible in high-risk patients. In an attempt to address some of the issues with EVAR 2, the SVS 
Outcomes Committee analyzed their Lifeline Registry (Sicard, 2006) and found that 565 of the 
,3000 patients in the registry met the high-risk criteria set out in EVAR 2, far exceeding the 
number of patients in the EVAR 2 trial. Sicard et al. reported that there was a significant 
difference in 30-day mortality (2.9%) in the investigational device exemption (IDE) trial 
registries compared to 9% in EVAR 2. Moreover, the 4-year survival rate for the IDE group was 
56% (based on all-cause mortality, not just aneurysm-related mortality), versus 36% in EVAR 2, 
so there was a difference of 20 percentage points between the 2 trials. One explanation for the 
large difference in both aneurysm-related and all-cause mortality rates between EVAR 2 and the 
US IDE data is that the EVAR-2 trial was dealing with sicker patients. Another possible 
explanation is that the actual medical care of these patients was different. The EVAR-2 trial 
participants explained the long delay between randomization and treatment because of the 
need to manage patient co-morbidities; they emphasized the need for optimization of the 
patient before the intervention. Despite a mean aneurysm diameter of 6.7 cm, EVAR was not 
done until a median of 57 days after randomization. During this time, 9 aneurysms ruptured, 
causing nearly half of the 20 aneurysm-related deaths in the EVAR group. Once the decision to 
intervene was taken in our study, the procedure was performed within 14 days, and despite 5 
ruptures occurring in the non-operative group within the first 6 months, no ruptures occurred 
preoperatively in the EVAR or open repair groups. It could then be argued that if patients are 
anatomically suitable for EVAR, they should be treated without delay. However, it is extremely 
important to adequately assess and improve patient fitness before intervention, which is 
especially true in very high-risk patients. All our patients were given best medical treatment, 
(Oaikhinan, 2004) and every effort was made to optimize cardio-respiratory and renal function 
preoperatively, which our extended mean length of hospital stay reflects. 
4.1 Benefit to the individual 
The debate over the relative long- or intermediate- term risks and benefits associated with 
intervention versus observation is especially pertinent in the context of high-risk patients. 
The improvement in QALY in the immediate postoperative period for both EVAR and OR 
in most studies reflects the relief a patient must feel at overcoming intervention and 
escaping a potentially lethal disease. (Malina, 2007; UK Small Aneurysm Trial Participants, 
1998) For some patients, the knowledge that they have a large or expanding aneurysm and 
the realization that outcomes following ruptured AAA repair are bleak may cause 
considerable psychological stress and impact significantly on their quality of life.  
Most studies have shown that quality of life is improved in the perioperative period 
following EVAR compared to OR, which is a reflection of the shorter hospital stay, reduced 
blood loss, early improvements in physical mobility and pain, as well as a likelihood for a 
patient to be discharged to home rather than to an institution. (Geraghty, 2003; Lee, 2004) 
However, most studies demonstrated no difference in QALY when patients are surveyed at 
remote time points.(EVAR trial-2 participants, 2005; Lottman, 2004; Prinssen, 2004) On the 
other hand, Aljabri et al. (Aljabri, 2006) and the DREAM trial investigators (Prinssen, 2004) 
reported that EVAR patients had a lower QALY 6 months after surgery than in OR patients. 
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Much criticism has been directed toward EVAR because of the impression that the need for 
long-term surveillance and risk of secondary interventions will reduce future quality of life. 
The DREAM investigators (Blankensteijn, 2005) reported that the rate of reintervention after 
EVAR in the first 9 months after randomization was almost 3 times the rate after open 
repair. High reintervention rates were a problem in EVAR 1 (EVAR trial-1 participants, 
2005) and are most certainly due to poor preoperative estimation of anatomical suitability. 
In EVAR 1, 54% of potentially eligible patients were found to be anatomically ‘‘suitable’’ for 
EVAR, but this proportion ranged from 6% to 100% across the 34 centers, illustrating the 
variation in assessing this important variable. In our study, the intervention-free survival 
rates at 4 years were similar for EVAR and OR. 
Our low secondary reintervention rate most certainly impacted positively on our quality 
of life analysis. We had only 3 reinterventions in our EVAR patients, 2 for type III 
endoleak. None of the 11 type II endoleaks required treatment. In our experience, 
complete obliteration of all patent branches is not warranted. (Dias, 2004; van Marrewijk, 
2004) Our policy is not to intervene either prophylactically or therapeutically for type II 
endoleaks unless there is a persistent increase in sac diameter .5 mm for 3 months; all of 
the type II endoleaks in this study resolved within 3 months, and there was no increase in 
sac diameter. 
4.2 Benefit to society 
The EVAR-1 investigators showed that aneurysm-related mortality stayed 3% lower with 
EVAR throughout the 4-year follow-up period. (EVAR trial-1 participants, 2005)  However, 
obtaining this benefit required a 33% increase in hospital costs without a sustained benefit in 
quality of life. Rationing parameters for healthcare resources are admittedly controversial 
and generate ethical dilemmas. It has been suggested that perhaps EVAR should be 
restricted to those patients who are ‘‘fit’’ for surgery, by whatever definition deemed 
appropriate, as the procedure, the endovascular devices, the continuing need for 
surveillance imaging, and possible secondary re-interventions are costly. 
To the contrary, we have shown that EVAR can be performed with clinical equivalence and 
enhances quality of life in high-risk patients. However, the benefit to the individual cannot 
be at the expense of the healthcare system. A report commissioned by the Belgian 
government and published in 2005 found that EVAR was not cost effective. (Bonneux, 2005) 
Multiple authors have reported that hospitals lose money on EVAR compared to earning 
significant profits from OR. In a comprehensive cost analysis, Bertges et al. (Bertges, 2003) 
analyzed the costs associated with EVAR in 221 Medicare patients and found that ‘‘mean 
total hospital cost was $22,999, and mean reimbursement, weighted by case mix, was 
$20,837, resulting in a net loss of $2162’’ per case. However, Patel et al. (Patel, 1999) in a 
hypothetical Markov model concluded that EVAR was cost effective, with a mean endograft 
cost of >$13,000 and overhead of an additional $1100. They used a baseline mortality rate of 
4.8% for OR and concluded that if OR could be done with comparable morbidity and 
mortality to EVAR, the cost-effectiveness of EVAR ceased to exist. Similarly, the Belgian 
report recommended that long-term mortality and morbidity must be lower to make EVAR 
a cost-effective alternative to OR. (Bonneux, 2005) The Belgian report found that although 
the endograft contributed most to the cost disparity between OR and EVAR, CT follow-up 
was the second most important determinant, contributing more to cost than secondary 
interventions or procedure-related complications. 
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Contrary to the predictions of Patel et al. (Patel, 1999) and the Belgian report, (Bonneux, 
2005) we found that despite no benefit in terms of freedom from MACE, EVAR was cost-
effective compared to OR even in this high-risk cohort. We used a comprehensive analysis 
of the cost benefit ratio of EVAR on a real patient cohort in an attempt to validate the cost-
effectiveness of EVAR. We found that the mean cost, including 4-year follow-up, was 
>€5,000 less with EVAR, giving a negative incremental cost-effectiveness ratio of €144,388 
per QALY gained. This is in part due to a financial deal with our graft providers, reduced 
hospital stay, minimal need for ICU facilities, increasing use of duplex in follow-up, and a 
low secondary reintervention rate. However, to ensure cost-effectiveness and to guarantee 
maximum impact of this technology, we believe it must be performed in high-volume 
centers, which is in line with recommendations from the Belgian report. (Bonneux) 
If we minimize perioperative problems, then the question that we really need to ask 
ourselves is which patients are going to die from something else before they benefit from the 
aneurysm repair? This question has not yet been answered by any trials or datasets and is 
fundamental to the treatment of aneurysm disease. From our data, the only factors that we 
identified as having a negative impact on both all-cause and aneurysm specific mortality 
were advanced age and large aneurysm diameter. 
The physician and patient must decide on an individual basis whether any aneurysm repair 
should be undertaken, or as EVAR 2 might suggest, whether the patient is so ill that treating 
the aneurysm would not confer any survival benefit. We reported our results over 48 
months, and although the 95% confidence intervals might suggest these to be simple 
speculative estimations, we strongly believe that our results reflect the reality that 
endovascular specialists face continually when dealing with high-risk patients. Our study 
may be underpowered due to the small sample size; however, the patient and family did 
take the lead in deciding which treatment best suited them. 
4.3 Conclusion 
We have shown that EVAR significantly reduces both long-term aneurysm-related and all-
cause mortality, with minimal operative mortality risk and a low secondary intervention 
rate. High-risk patients ought to be managed in high-volume centers where they can benefit 
from specialized multidisciplinary care with low perioperative morbidity and mortality 
rates. EVAR and OR options are plausible and both can be tailored to the patient. In 
financial terms, our hospital has profited from our EVAR program. High patient turnover 
rates and low use of ICU facilities have certainly contributed to its profitability and overall 
benefit to the individual, health economy, and the community as a whole. We have shown 
EVAR to be a safe, durable, and feasible option for high-risk patients. It significantly 
improves quality of life compared to open repair or best medical therapy and can be 
performed with minimal risk of major complications or secondary intervention. The results 
of EVAR are exceptional and have positively influenced the choices available to the patients 
and their referring primary physicians. 
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